The cost-benefit issue is real, but the framing here is wrong.
In GBM and other difficult cancers, a durable survival tail is not a minor outcome. It is exactly what medicine is trying to create. The correct comparison is not against cancers with many good options. The correct comparison is against deadly cancers where long-term survival remains rare and current treatments often fail.
DCVax-L also should not be analyzed only as a stand-alone GBM treatment. Dendritic-cell vaccination has a strong probability of becoming a broader cancer-treatment platform, especially in cancers where existing treatments are weak, toxic, temporary, or nonexistent. The combination data with Poly-ICLC points to something larger: this approach may help unlock stronger immune responses across multiple tumor types.
That matters scientifically, clinically, and economically. A treatment that teaches the immune system to recognize a patient’s own tumor is not just another drug. It is a way to expose the tumor, activate immune memory, and build rational combinations with checkpoint inhibitors, immune stimulants, radiation, chemotherapy, and other therapies.
The cost argument also ignores scale. Early personalized therapies are expensive because they are produced in limited volumes, with complex logistics and specialized processing. As manufacturing scales, processes improve, automation increases, capacity expands, and unit costs can come down. Economies of scale matter here, especially if the same platform can support multiple cancers.
The cost argument also ignores the existing treatment landscape. Tumor Treating Fields is already expensive. If it got the same results and when it does, it is actually much MORE expensive than DCVax-L. Many oncology treatments are extremely expensive. If those treatments produced the kind of durable survival signals now being watched with dendritic-cell vaccines and combinations, no one would dismiss them as economically inefficient simply because they were effective but cost money to develop and improve. We lose the forest for the trees when we compare to ineffective but expensive treatments that are not systemic and do not have further pathways to not just improve outcomes, but expand our understanding of the fundamentals of the human immune system to continuously improve outcomes into the future. DCVax-L is an amazing tool especially because it is so fundamental in nature.
Personalized treatment is not automatically bad economics. Bad economics is paying high prices for weak benefit. Good economics is paying for meaningful survival in lethal cancers with few options.
The real question is simple: does DCVax-L meaningfully extend survival, create a durable survival tail, maintain a favorable safety profile, become stronger in rational combinations, and scale into a more efficient manufacturing model?
That is the cost-benefit discussion. Not “personalized treatment costs money, therefore it is inefficient.”
Bullish
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
